Deutsche Bank AG raised its stake in shares of T2 Biosystems Inc (NASDAQ:TTOO) by 101.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 157,785 shares of the medical equipment provider’s stock after purchasing an additional 79,311 shares during the quarter. Deutsche Bank AG’s holdings in T2 Biosystems were worth $474,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of TTOO. Janney Montgomery Scott LLC acquired a new position in shares of T2 Biosystems during the 4th quarter worth about $37,000. Bell & Brown Wealth Advisors LLC acquired a new position in shares of T2 Biosystems during the 4th quarter worth about $38,000. Private Advisor Group LLC acquired a new position in shares of T2 Biosystems during the 4th quarter worth about $45,000. Creative Planning grew its position in shares of T2 Biosystems by 28.0% during the 4th quarter. Creative Planning now owns 19,200 shares of the medical equipment provider’s stock worth $58,000 after buying an additional 4,200 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of T2 Biosystems during the 4th quarter worth about $67,000. Institutional investors own 48.75% of the company’s stock.
NASDAQ:TTOO opened at $2.57 on Thursday. T2 Biosystems Inc has a fifty-two week low of $2.41 and a fifty-two week high of $9.98. The company has a current ratio of 0.81, a quick ratio of 1.03 and a debt-to-equity ratio of 0.04. The stock has a market cap of $111.29 million, a PE ratio of -2.04 and a beta of 1.77.
Several equities analysts have recently issued reports on TTOO shares. HC Wainwright restated a “buy” rating and set a $11.00 target price (down from $14.00) on shares of T2 Biosystems in a research report on Friday, March 8th. Zacks Investment Research cut T2 Biosystems from a “hold” rating to a “sell” rating in a report on Tuesday, March 5th. ValuEngine cut T2 Biosystems from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Cantor Fitzgerald reiterated a “buy” rating and set a $10.00 price objective on shares of T2 Biosystems in a report on Friday, May 3rd. Finally, Alliance Global Partners assumed coverage on T2 Biosystems in a report on Thursday, May 16th. They set a “buy” rating and a $5.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $7.79.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.baseballdailydigest.com/news/2019/05/23/deutsche-bank-ag-has-474000-stake-in-t2-biosystems-inc-ttoo.html.
About T2 Biosystems
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.
Featured Story: Why do companies pay special dividends?
Want to see what other hedge funds are holding TTOO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for T2 Biosystems Inc (NASDAQ:TTOO).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.